on Newron Pharmaceuticals S.p.A. (isin : IT0004147952)
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Newron Pharmaceuticals S.p.A. will host its 2024 Investor Day on June 25, 2024 in New York City. The event begins at 9:00 AM EDT and will be available via live webcast. This session will focus on the company's evenamide program for treating treatment-resistant schizophrenia.
Leading experts including Dr. Anthony Grace from the University of Pittsburgh, Dr. John Kane from Hofstra/Northwell, and Dr. Stephen R. Marder from UCLA, will present their findings. They will review Phase III data and discuss new neurobiological concepts and the unmet needs in treating schizophrenia.
CEO Stefan Weber and Chief Medical Officer Ravi Anand of Newron will also provide updates on evenamide’s clinical and registration program. The event is open to institutional investors, business partners, analysts and media representatives. Pre-registration is required for attendance.
Access to the live webcast and international dial-in options are available. The webcast will be archived on Newron’s website for one month post-event.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Newron Pharmaceuticals S.p.A. news